238 related articles for article (PubMed ID: 34641481)
1. Total Syntheses of Pladienolide-Derived Spliceosome Modulators.
Sim J; Jang E; Kim HJ; Jeon H
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641481
[TBL] [Abstract][Full Text] [Related]
2. Expedient Total Syntheses of Pladienolide-Derived Spliceosome Modulators.
Rhoades D; Rheingold AL; O'Malley BW; Wang J
J Am Chem Soc; 2021 Apr; 143(13):4915-4920. PubMed ID: 33755462
[TBL] [Abstract][Full Text] [Related]
3. Enantioselective total synthesis of pladienolide B: a potent spliceosome inhibitor.
Ghosh AK; Anderson DD
Org Lett; 2012 Sep; 14(18):4730-3. PubMed ID: 22954141
[TBL] [Abstract][Full Text] [Related]
4. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.
Kashyap MK; Kumar D; Villa R; La Clair JJ; Benner C; Sasik R; Jones H; Ghia EM; Rassenti LZ; Kipps TJ; Burkart MD; Castro JE
Haematologica; 2015 Jul; 100(7):945-54. PubMed ID: 25862704
[TBL] [Abstract][Full Text] [Related]
5. Test-firing ammunition for spliceosome inhibition in cancer.
Dehm SM
Clin Cancer Res; 2013 Nov; 19(22):6064-6. PubMed ID: 24097858
[TBL] [Abstract][Full Text] [Related]
6. Spliceostatins and Derivatives: Chemical Syntheses and Biological Properties of Potent Splicing Inhibitors.
Ghosh AK; Mishevich JL; Jurica MS
J Nat Prod; 2021 May; 84(5):1681-1706. PubMed ID: 33974423
[TBL] [Abstract][Full Text] [Related]
7. Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status.
Suda K; Rozeboom L; Yu H; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
PLoS One; 2017; 12(2):e0172209. PubMed ID: 28192473
[TBL] [Abstract][Full Text] [Related]
8. A synthetic entry to pladienolide B and FD-895.
Mandel AL; Jones BD; La Clair JJ; Burkart MD
Bioorg Med Chem Lett; 2007 Sep; 17(18):5159-64. PubMed ID: 17681759
[TBL] [Abstract][Full Text] [Related]
9. Splicing factor SF3b as a target of the antitumor natural product pladienolide.
Kotake Y; Sagane K; Owa T; Mimori-Kiyosue Y; Shimizu H; Uesugi M; Ishihama Y; Iwata M; Mizui Y
Nat Chem Biol; 2007 Sep; 3(9):570-5. PubMed ID: 17643112
[TBL] [Abstract][Full Text] [Related]
10. The spliceosome inhibitors isoginkgetin and pladienolide B induce ATF3-dependent cell death.
Vanzyl EJ; Sayed H; Blackmore AB; Rick KRC; Fernando P; McKay BC
PLoS One; 2020; 15(12):e0224953. PubMed ID: 33370278
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric analysis identifies changes in S and M phases as novel cell cycle alterations induced by the splicing inhibitor isoginkgetin.
Vanzyl EJ; Rick KRC; Blackmore AB; MacFarlane EM; McKay BC
PLoS One; 2018; 13(1):e0191178. PubMed ID: 29338026
[TBL] [Abstract][Full Text] [Related]
12. Enantioselective synthesis of pladienolide B and truncated analogues as new anticancer agents.
Kumar VP; Chandrasekhar S
Org Lett; 2013 Jul; 15(14):3610-3. PubMed ID: 23822896
[TBL] [Abstract][Full Text] [Related]
13. Pre-mRNA splicing-modulatory pharmacophores: the total synthesis of herboxidiene, a pladienolide-herboxidiene hybrid analog and related derivatives.
Lagisetti C; Yermolina MV; Sharma LK; Palacios G; Prigaro BJ; Webb TR
ACS Chem Biol; 2014 Mar; 9(3):643-8. PubMed ID: 24377313
[TBL] [Abstract][Full Text] [Related]
14. Total Synthesis of the Spliceosome Modulator Pladienolide B via Asymmetric Alcohol-Mediated syn- and anti-Diastereoselective Carbonyl Crotylation.
Yoo M; Krische MJ
Angew Chem Int Ed Engl; 2021 Jun; 60(25):13923-13928. PubMed ID: 33794050
[TBL] [Abstract][Full Text] [Related]
15. Macrolactin Antibiotics: Amazing Natural Products.
Ortiz A; Sansinenea E
Mini Rev Med Chem; 2020; 20(7):584-600. PubMed ID: 31804166
[TBL] [Abstract][Full Text] [Related]
16. A Carbohydrate-Derived Splice Modulator.
Dhar S; La Clair JJ; León B; Hammons JC; Yu Z; Kashyap MK; Castro JE; Burkart MD
J Am Chem Soc; 2016 Apr; 138(15):5063-8. PubMed ID: 27058259
[TBL] [Abstract][Full Text] [Related]
17. Antitumor compounds based on a natural product consensus pharmacophore.
Lagisetti C; Pourpak A; Jiang Q; Cui X; Goronga T; Morris SW; Webb TR
J Med Chem; 2008 Oct; 51(19):6220-4. PubMed ID: 18788726
[TBL] [Abstract][Full Text] [Related]
18. Biological validation that SF3b is a target of the antitumor macrolide pladienolide.
Yokoi A; Kotake Y; Takahashi K; Kadowaki T; Matsumoto Y; Minoshima Y; Sugi NH; Sagane K; Hamaguchi M; Iwata M; Mizui Y
FEBS J; 2011 Dec; 278(24):4870-80. PubMed ID: 21981285
[TBL] [Abstract][Full Text] [Related]
19. The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action.
Finci LI; Zhang X; Huang X; Zhou Q; Tsai J; Teng T; Agrawal A; Chan B; Irwin S; Karr C; Cook A; Zhu P; Reynolds D; Smith PG; Fekkes P; Buonamici S; Larsen NA
Genes Dev; 2018 Feb; 32(3-4):309-320. PubMed ID: 29491137
[TBL] [Abstract][Full Text] [Related]
20. The SF3b Complex is an Integral Component of the Spliceosome and Targeted by Natural Product-Based Inhibitors.
Larsen NA
Subcell Biochem; 2021; 96():409-432. PubMed ID: 33252738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
